You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

 

710 Results
Regimen
Cancer Type:
Genitourinary, 
Prostate
Intent: Palliative
Funding:
ODB - General Benefit
    abiraterone
Exceptional Access Program
    olaparib - In combination with abiraterone, and prednisone or prednisolone for the treatment of metastatic castration resistant prostate cancer (mCRPC), based on criteria
ODB - General Benefit
    prednisone
Dec 2024
Guidelines and Advice
Drug
Other Name(s): Votrient®
Dec 2024
Regimen
Cancer Type:
Genitourinary, 
Renal cell / Kidney
Intent: Palliative
Funding:
Exceptional Access Program
    pazopanib - For first-line treatment of advanced or metastatic renal cell carcinoma of clear cell histology in patients with good performance status (ECOG 0-1), with specific criteria
Dec 2024
Regimen
Cancer Type:
Sarcoma, 
Soft Tissue
Intent: Palliative
Dec 2024
Senior Scientist, Indigenous Cancer Care Unit, Acute and Hospital-Based Care, Ontario Health Lead Scientist amanda.sheppard@ontariohealth.ca
Senior chercheuse, Unité des soins de cancérologie chez les peuples autochtones, Soins aigus et hospitaliers, Santé Ontario Chercheuse...
Senior Scientist, Acute and Hospital-Based Care, Ontario Health Senior Scientistanna.chiarelli@ontariohealth.ca
Chercheuse principale, Soins aigus et hospitaliers, Santé Ontario Chercheuse principaleanna.chiarelli@ontariohealth.ca
Drug
Other Name(s): Taxol®
Nov 2024

Pages